CARMHA Research Seminars

The contaminated illicit drug supply: drug overdose risks associated with known and unknown exposure to fentanyl among people who inject drugs in Vancouver

Presenters: Dr. Kanna Hayashi
Date
: June 6, 2019
Time
: 12-1pm
Location
: SFU Harbour Centre, Room 2200
BlueJeans:
https://bluejeans.com/603206603

Abstract:

Illicitly-manufactured fentanyl continues to contaminate the illicit drug markets and fuel the opioid overdose crisis in North America. However, little is known about the extent to which individuals knowingly consume fentanyl. Therefore, the present study compared self-reported exposure to fentanyl among a sample of 592 people who inject drugs (PWID) in Vancouver with results obtained via a urine drug screen (UDS) that detects recent fentanyl exposure. Multivariable logistic regression was used to identify demographic, behavioral and social-structural factors associated with known exposure (i.e., UDS positive for fentanyl and self-reporting fentanyl exposure in the past 3 days) and unknown exposure to fentanyl (i.e., UDS positive for fentanyl and self-reporting no fentanyl exposure in the past 3 days), respectively, compared against no fentanyl exposure. Preliminary results and the potential implications will be presented.

Brief Bio:

Dr. Kanna Hayashi, PhD, is the St. Paul’s Hospital Chair in Substance Use Research, and Assistant Professor in the Faculty of Health Sciences, Simon Fraser University and a Research Scientist with the BC Centre on Substance Use. She is a substance use epidemiologist and currently leads the Vancouver Injection Drug Users Study (VIDUS), a U.S. National Institutes of Health-funded ongoing prospective cohort study of more than 1,000 people who inject drugs in Vancouver, to investigate the natural history of injection drug use. She also has substance use-related research experience in Asia, including Thailand and Japan. Her primary research interests and expertise include substance use epidemiology, community-based research, public health and human rights, and health services for drug-using populations.